Literature DB >> 24886787

Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial.

Amit X Garg1, P J Devereaux2, Salim Yusuf2, Meaghan S Cuerden3, Chirag R Parikh4, Steven G Coca4, Michael Walsh2, Richard Novick5, Richard J Cook6, Anil R Jain7, Xiangbin Pan8, Nicolas Noiseux9, Karel Vik10, Noedir A Stolf11, Andrew Ritchie12, Roberto R Favaloro13, Sirish Parvathaneni14, Richard P Whitlock15, Yongning Ou16, Mitzi Lawrence16, Andre Lamy15.   

Abstract

IMPORTANCE: Most acute kidney injury observed in the hospital is defined by sudden mild or moderate increases in the serum creatinine concentration, which may persist for several days. Such acute kidney injury is associated with lower long-term kidney function. However, it has not been demonstrated that an intervention that reduces the risk of such acute kidney injury better preserves long-term kidney function.
OBJECTIVES: To characterize the risk of acute kidney injury with an intervention in a randomized clinical trial and to determine if there is a difference between the 2 treatment groups in kidney function 1 year later. DESIGN, SETTING, AND PARTICIPANTS: The Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY) enrolled 4752 patients undergoing first isolated coronary artery bypass graft (CABG) surgery at 79 sites in 19 countries. Patients were randomized to receive CABG surgery either with a beating-heart technique (off-pump) or with cardiopulmonary bypass (on-pump). From January 2010 to November 2011, 2932 patients (from 63 sites in 16 countries) from CORONARY were enrolled into a kidney function substudy to record serum creatinine concentrations during the postoperative period and at 1 year. The last 1-year serum creatinine concentration was recorded on January 18, 2013. MAIN OUTCOMES AND MEASURES: Acute kidney injury within 30 days of surgery (≥50% increase in serum creatinine concentration from prerandomization concentration) and loss of kidney function at 1 year (≥20% loss in estimated glomerular filtration rate from prerandomization level).
RESULTS: Off-pump (n = 1472) vs on-pump (n = 1460) CABG surgery reduced the risk of acute kidney injury (17.5% vs 20.8%, respectively; relative risk, 0.83 [95% CI, 0.72-0.97], P = .01); however, there was no significant difference between the 2 groups in the loss of kidney function at 1 year (17.1% vs 15.3%, respectively; relative risk, 1.10 [95% CI, 0.95-1.29], P = .23). Results were consistent with multiple alternate continuous and categorical definitions of acute kidney injury or kidney function loss, and in the subgroup with baseline chronic kidney disease. CONCLUSIONS AND RELEVANCE: Use of off-pump compared with on-pump CABG surgery reduced the risk of postoperative acute kidney injury, without evidence of better preserved kidney function with off-pump CABG surgery at 1 year. In this setting, an intervention that reduced the risk of mild to moderate acute kidney injury did not alter longer-term kidney function. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00463294.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24886787     DOI: 10.1001/jama.2014.4952

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  55 in total

1.  Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial.

Authors:  Amit X Garg; Neal Badner; Sean M Bagshaw; Meaghan S Cuerden; Dean A Fergusson; Alexander J Gregory; Judith Hall; Gregory M T Hare; Boris Khanykin; Shay McGuinness; Chirag R Parikh; Pavel S Roshanov; Nadine Shehata; Jessica M Sontrop; Summer Syed; George I Tagarakis; Kevin E Thorpe; Subodh Verma; Ron Wald; Richard P Whitlock; C David Mazer
Journal:  J Am Soc Nephrol       Date:  2019-06-20       Impact factor: 10.121

2.  Application of new acute kidney injury biomarkers in human randomized controlled trials.

Authors:  Chirag R Parikh; Dennis G Moledina; Steven G Coca; Heather R Thiessen-Philbrook; Amit X Garg
Journal:  Kidney Int       Date:  2016-04-23       Impact factor: 10.612

3.  Postoperative Renal Outcomes of On-Pump Beating-Heart versus Cardioplegic Arrest Coronary Artery Bypass Grafting.

Authors:  Shao-Wei Chen; Chih-Hsiang Chang; Yen Chu; Victor Chien-Chia Wu; Cheng-Chia Lee; Dong-Yi Chen; Pyng-Jing Lin; Feng-Chun Tsai
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 4.  AKI associated with cardiac surgery.

Authors:  Robert H Thiele; James M Isbell; Mitchell H Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 8.237

5.  Ptolemy and Copernicus Revisited: The Complex Interplay between the Kidneys and Heart Failure.

Authors:  Steven G Coca
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-17       Impact factor: 8.237

6.  Clinical trials: Off-pump coronary artery bypass graft surgery reduces postoperative AKI risk.

Authors:  Peter Sidaway
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

7.  Commentary: We have mastered off-pump coronary artery bypass grafting technique, but not the indications for it.

Authors:  Mario Gaudino; Berhane Worku
Journal:  J Thorac Cardiovasc Surg       Date:  2019-04-24       Impact factor: 5.209

Review 8.  The Role of Acute Kidney Injury in Chronic Kidney Disease.

Authors:  Raymond K Hsu; Chi-Yuan Hsu
Journal:  Semin Nephrol       Date:  2016-07       Impact factor: 5.299

Review 9.  Long-Term Outcomes in Patients with Acute Kidney Injury.

Authors:  Rebecca A Noble; Bethany J Lucas; Nicholas M Selby
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-19       Impact factor: 8.237

10.  Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data.

Authors:  Morgan E Grams; Yingying Sang; Josef Coresh; Shoshana Ballew; Kunihiro Matsushita; Miklos Z Molnar; Zoltan Szabo; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Kidney Dis       Date:  2015-09-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.